Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3640254 monotherapy in treatment-naive adults with HIV-1 infection
2018-002208-15Phase 2Completed
- Sponsor
- ViiV Healthcare
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Human immunodeficiency virus infection type 1 and human immunodeficiency virus infection (HIV) comparing GSK3640254 with Placebo (2 arms). Primary endpoint: Maximum change from baseline in plasma HIV-1 RNA. Started Nov 2018; status: completed.
02
Drugs
fipravirimat
03
Conditions
Human immunodeficiency virus infection type 1human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2018-002208-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002208-15.